慢性HBV感染者获得病毒学应答后肝纤维化/肝硬化逆转因素的分析

杨艳; 张新

doi:10.3969/j.issn.1001-5256.2018.07.038

慢性HBV感染者获得病毒学应答后肝纤维化/肝硬化逆转因素的分析

DOI: 10.3969/j.issn.1001-5256.2018.07.038

杨艳,
张新

哈尔滨医科大学附属第一医院感染科

详细信息

中图分类号: R512.62;R575.2
计量
- 文章访问数: 1388
- HTML全文浏览量: 24
- PDF下载量: 317
- 被引次数: 0
出版历程
- 收稿日期: 2017-12-11
- 出版日期: 2018-07-20

Analysis of reversal factors associated with liver fibrosis/cirrhosis in patients with chronic HBV infection after achieving virologic response

Yang Yan,
Zhang Xin

Department of Infectious Diseases, The First Affiliated Hospital of Harbin Medical University

摘要

摘要: 慢性HBV感染可导致不同程度的肝纤维化,而肝纤维化是肝硬化发生的重要病理基础,控制甚至逆转肝纤维化对于降低肝硬化、肝细胞癌等终末期疾病的发病率尤为重要。慢性HBV感染者经长期抗HBV治疗获得病毒学应答后肝脏炎症消退,肝纤维化甚至肝硬化可得到不同程度的逆转,甚至完全恢复至正常结构,具体机制及相关影响因素目前尚不十分明确。归纳并分析了近年来关于慢性HBV感染者获得病毒学应答后肝纤维化/肝硬化逆转的相关研究,总结了可能与慢性HBV感染者抗病毒治疗后肝纤维化/肝硬化逆转的相关影响因素,包括年龄、性别、宿主因素、病毒因素、治疗因素、代谢相关因素等,但仍有其他的相关影响因素有待进一步研究。
- 肝炎病毒,乙型 /
- 肝硬化 /
- 病毒学应答 /
- 综述
Abstract: Chronic hepatitis B virus ( HBV) infection can lead to varying degrees of liver fibrosis, which is an important pathological basis of liver cirrhosis. The incidence of end-stage liver diseases such as liver cirrhosis and hepatocellular carcinoma can be reduced by controlling and even reversing liver fibrosis. After achieving virologic response ( VR) to long-term anti-HBV therapy, patients with chronic HBV infection have resolution of inflammation, varying degrees of reversal of liver fibrosis and even liver cirrhosis, or even complete recovery of normal liver structure, but the specific mechanism and influencing factors remain unclear. This article reviews the recent studies on the reversal of liver fibrosis/cirrhosis after achieving VR in patients with chronic HBV infection, and summarizes the influencing factors for reversal of liver fibrosis/cirrhosis in patients with chronic HBV infection after antiviral therapy, including age, sex, host factors, viral factors, therapeutic factors, and metabolic factors, but a lot of factors still await further investigation.
- hepatitis B Virus /
- liver cirrhosis /
- virological response /
- review

HTML全文

参考文献(30)

[1]OKADA M, ENOMOTO M, KAWADA N, et al.Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis[J].Expert Rev Gastroenterol Hepatol, 2017, 11 (12) :1095-1104.

[2]WANG BQ, SUN YM, YOU H, et al.Pathological assessment of liver fibrosis regression[J].J Clin Hepatol, 2017, 33 (3) :435-437. (in Chinese) 王冰琼, 孙亚朦, 尤红, 等.肝纤维化逆转的病例评估[J].临床肝胆病杂志, 2017, 33 (3) :435-437.

[3]BEDOSSA P.Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J].Liver Int, 2015, 35 (Suppl 1) :78-81.

[4]SOHRABPOUR A, MOHAMADNEJAD M, MALEKZADEH R.Review article:The reversibility of cirrhosis[J].Aliment Pharmacol Ther, 2012, 36 (9) :824-832.

[5]XU B, LIN L, XU G, et al.Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B[J].J Gastroenterol Hepatol, 2015, 30 (2) :372-378.

[6]WONG GL.Prediction of fibrosis progression in chronic viral hepatitis[J].Clin Mol Hepatol, 2014, 20 (3) :228-236.

[7]PAPACHRYSOS N, HYTIROGLOUB P, PAPALAVRENTIOS L, et al.Antiviral therapy leads to histological improvement of HBe Ag-negative chronic hepatitis B patients[J].Ann Gastroenterol, 2015, 28 (3) :374-378.

[8]TSAI NC, MARCELLIN P, BUTI M, et al.Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in asians with chronic hepatitis B[J].Dig Dis Sci, 2014, 60 (1) :260-268.

[9]European Association For The Study Of The Liver.EASL clinical practice guidelines:Management of chronic hepatitis B virus infection[J].J Hepatol, 2012, 57 (1) :167-185.

[10]SETO WK, FUNG J, CHEUNG KS, et al.Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B[J].Aliment Pharmacol Ther, 2016, 44 (10) :1071-1079.

[11]WANG Y, LIANG X, YANG JL, et al.Improved performance of quantitative collagen parameters versus standard histology in longitudinal assessment of non-advanced liver fibrosis for chronic hepatitis B[J].J Viral Hepat, 2017.[Epub ahead of print]

[12]HOU JL, GAO ZL, XIE Q, et al.Tenofovir disoproxil fumaratevsadefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks:A randomized controlled trial[J].J Viral Hepat, 2015, 22 (2) :85-93.

[13]BOURLIERE M, KAHLOUN A, GASCOU-TESSONNIER G.Analogs and fibrosis regression in hepatitis B[J].Gastroenterol Clin Biol, 2009, 33 (10-11) :923-929.

[14]DUCANCELLE A, PIVERT A, BERTRAIS S, et al.Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity[J].J Gastroenterol Hepatol, 2016, 31 (10) :1750-1756.

[15]BROWN A, GOODMAN Z.Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs[J].Expert Rev Gastroenterol Hepatol, 2012, 6 (2) :187-198.

[16]HONDA K, SEIKE M, MURAKAMI K.Benefits of nucleos (t) ide analog treatments for hepatitis B virus-related cirrhosis[J].World J Hepatol, 2015, 7 (22) :2404-2410.

[17]CHANG TT, GISH R, DE MAN R, et al.A comparison of entecavir and lamivudine for HBe Ag-positive chronic hepatitis B[J].N Engl J Med, 2006, 354 (10) :1001-1010.

[18]CHIEN RN, LIAW YF.Nucleos (t) ide analogues for hepatitis B virus:Strategies for long-term success[J].Best Pract Res Clin Gastroenterol, 2008, 22 (6) :1081-1092.

[19]ZENG J, CAI S, LIU J, et al.Dynamic changes in liver stiffness measured by transient elastography predict clinical outcomes among patients with chronic hepatitis B[J].J Ultrasound Med, 2017, 36 (2) :261-268.

[20]LI X, JIE Y, YOU X, et al.Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy[J].Int J Clin Exp, 2015, 8 (11) :21062-21070.

[21]LI ZC, CHEN ZX, WU ZY, et al.Effect of pegylated interferonα-2a combined with entecavir on hepatic function and hepatic fibrosis in patients with chronic hepatitis B[J].Anhui Med Pharm J, 2017, 21 (8) :1490-1493. (in Chinese) 李哲成, 陈朝霞, 吴昭颐, 等.聚乙二醇干扰素α-2a联合恩替卡韦对慢性乙型肝炎病人肝功能及肝纤维化的影响[J].安徽医药, 2017, 21 (8) :1490-1493.

[22]DIENSTAG JL, GOLDIN RD, HEATHCOTE EJ, et al.Histological outcome during long-term lamivudine therapy[J].Gastroenterology, 2003, 124 (1) :105-117.

[23]HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ, et al.Long-term therapy with adefovir dipivoxilfor HBe Ag-negative chronic hepatitis B for up to 5 years[J].Gastroenterology, 2006, 131 (6) :1743-1751.

[24]JIANG JY.A following up study on postponing hepatic fibrosis in patients with chronic hepatitis B with the Fuzheng Huayu capsule plus antiviral therapy[J].Clin J Chin Med, 2017, 9 (5) :14-16. (in Chinese) 蒋金艳.扶正化瘀胶囊联合抗病毒治疗延缓慢性乙肝患者肝纤维化病变的随访研究[J].中医临床研究, 2017, 9 (5) :14-16.

[25]WANG CX, LUO WS, GUO X, et al.Systematic review of combinative effects of anluo huaxian pills with nucleotide analogues on liver fibrosis due to chronic hepatitis B[J].Chin J Exp Med Formul, 2017, 7 (21) :203-209. (in Chinese) 王晨晓, 罗伟生, 郭潇, 等.安络化纤丸联合核苷 (酸) 药物治疗慢性乙型肝炎肝纤维化的系统评价[J].中国实验方剂学杂志, 2017, 7 (21) :203-209.

[26]WU YZ, YANG L, ZHAI YF, et al.Therapeutic effect of autologous bone marrow mesenchymal stem cells on hepatic fibrosis, liver function, MELD score and 1-year survival rate in patients with decompensated hepatitis B[J].Chin J Tissue Engineer Res, 2017, 21 (12) :2049-2055. (in Chinese) 吴玉卓, 杨乐, 翟玉峰, 等.自体骨髓间充质干细胞治疗乙型肝炎失代偿期患者:肝纤维化、肝功能、MELD评分及1年生存率分析[J].中国组织工程研究, 2017, 21 (12) :2049-2055.

[27]DENG QZ, CAI T, ZHANG S, et al.Effects of autologous peripheral stem cell transplantation on acoustic radiation force impulse in patients with HBV-related decompedsated cirrhosis[J].Chin J Hepatol, 2015, 23 (11) :832-836. (in Chinese) 邓勤智, 蔡挺, 张顺, 等.自体外周血干细胞移植对乙型肝炎肝硬化失代偿期患者肝脏声脉冲辐射力成像的影响[J].中华肝脏病杂志, 2015, 23 (11) :832-836.

[28]ZHANG W, JIA JD.Pathogenesis and new therapeutic targets of liver fibrosis[J].J Clin Hepatol, 2017, 33 (3) :409-412. (in Chinese) 张伟, 贾继东.肝纤维化的发病机制及治疗新靶点[J].临床肝胆病杂志, 2017, 33 (3) :409-412.

[29]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:A 5-year open-label follow-up study[J].Lancet, 2013, 381:468-475.

[30]HODGE A, LIM S, GOH E, et al.Coffee intake is associated with a lower liver stiffness in patients with non-alcoholic fatty liver disease, hepatitis C, and hepatitis B[J].Nutrients, 2017, 9 (1) .pii:E56.

施引文献

资源附件(0)

访问统计